Tinea capitis in early infancy treated with itraconazole: a pilot study

J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1161-3. doi: 10.1111/j.1468-3083.2009.03271.x. Epub 2009 Apr 23.


Background: Tinea capitis is the most common fungal infection of the scalp in childhood, but a very rare disorder in the first year of life.

Objective: To evaluate the efficacy, tolerability and safety of itraconazole in 7 children aged between 3 and 46 weeks (median: 36 weeks) suffering from tinea capitis caused by Microsporum canis.

Methods: Prospective case note study. In all patients KOH testing and fungal cultivation on Sabouraud dextrose agar were performed.

Results: 7 patients (5 girls and 2 boys) were included in the period between 2001 and 2008. The causative etiologic agent was Microsporum canis in all children. The patients received itraconazole 5mg/kg bodyweight daily for 3 to 6 weeks with no clinically side effects being noted. In all patients clinical and mycological cure could be achieved.

Conclusion: Itraconazole proved to be a safe and effective treatment option for Microsporum canis induced tinea capitis in children in their first year of life.

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Itraconazole / therapeutic use*
  • Male
  • Pilot Projects
  • Prospective Studies
  • Tinea Capitis / drug therapy*


  • Antifungal Agents
  • Itraconazole